These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210 [TBL] [Abstract][Full Text] [Related]
44. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Muehler A; Peelen E; Kohlhof H; Gröppel M; Vitt D Mult Scler Relat Disord; 2020 Aug; 43():102129. PubMed ID: 32428844 [TBL] [Abstract][Full Text] [Related]
45. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Hoffmann HH; Kunz A; Simon VA; Palese P; Shaw ML Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5777-82. PubMed ID: 21436031 [TBL] [Abstract][Full Text] [Related]
46. Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. Cheung NN; Lai KK; Dai J; Kok KH; Chen H; Chan KH; Yuen KY; Kao RYT J Gen Virol; 2017 May; 98(5):946-954. PubMed ID: 28555543 [TBL] [Abstract][Full Text] [Related]
47. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022). Gehlot P; Vyas VK Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439 [TBL] [Abstract][Full Text] [Related]
48. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans. Zameitat E; Gojković Z; Knecht W; Piskur J; Löffler M FEBS J; 2006 Jul; 273(14):3183-91. PubMed ID: 16774642 [TBL] [Abstract][Full Text] [Related]
49. [Stimulation of the antiviral innate immune response by pyrimidine biosynthesis inhibitors: a surprise of phenotypic screening]. Vidalain PO; Lucas-Hourani M; Helynck O; Tangy F; Munier-Lehmann H Med Sci (Paris); 2015 Jan; 31(1):98-104. PubMed ID: 25658737 [TBL] [Abstract][Full Text] [Related]
50. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods. Higgins WT; Vibhute S; Bennett C; Lindert S J Chem Inf Model; 2024 Jan; 64(2):435-448. PubMed ID: 38175956 [TBL] [Abstract][Full Text] [Related]
51. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. Boschi D; Pippione AC; Sainas S; Lolli ML Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612 [TBL] [Abstract][Full Text] [Related]
52. Cyanorona-20: The first potent anti-SARS-CoV-2 agent. Rabie AM Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016 [TBL] [Abstract][Full Text] [Related]
53. The dihydroorotate dehydrogenases: Past and present. Reis RAG; Calil FA; Feliciano PR; Pinheiro MP; Nonato MC Arch Biochem Biophys; 2017 Oct; 632():175-191. PubMed ID: 28666740 [TBL] [Abstract][Full Text] [Related]
54. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor. Alberti M; Sainas S; Ronchi E; Lolli ML; Boschi D; Rizzi M; Ferraris DM; Miggiano R FEBS Lett; 2023 Aug; 597(16):2119-2132. PubMed ID: 37278160 [TBL] [Abstract][Full Text] [Related]
55. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997 [TBL] [Abstract][Full Text] [Related]
57. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo. Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345 [TBL] [Abstract][Full Text] [Related]
58. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells. Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676 [TBL] [Abstract][Full Text] [Related]
59. 3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide. Li SL; He MY; Du HG Int J Mol Sci; 2011; 12(5):2982-93. PubMed ID: 21686163 [TBL] [Abstract][Full Text] [Related]
60. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]